Active	Status	Sponsor type	Region	Phase	Filter
6 Active 5 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   - « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Purim, Ofer
NCT04759664: LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC	Recruiting	2	117	US, RoW	LUT014 Gel (Dose 1), LUT014 Gel (Dose 2), Placebo	Lutris Pharma Ltd.	EGFRI Induced Acneiform Lesions	03/24	05/24
NCT06478862: Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy	Active, not recruiting	2	20	RoW	Promitil, Pegylated Liposomal Mitomycin-C Lipid-based Prodrug	Lipomedix Pharmaceuticals Inc.	Cancer of Ovary, Pancreatic Ductal Adenocarcinoma	06/26	01/27
Sapir, Eli
NANORAY-312, NCT04892173 / 2021-002163-22: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC	Recruiting	3	500	Europe, Japan, US, RoW	JNJ-90301900 (NBTXR3), Functionalized hafnium oxide nanoparticles, NBTXR3, Cetuximab, Erbitux, Radiation Therapy	Johnson & Johnson Enterprise Innovation Inc., Nanobiotix SA	Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged	06/26	06/27
Ryvo, Larisa
NCT04759664: LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC	Recruiting	2	117	US, RoW	LUT014 Gel (Dose 1), LUT014 Gel (Dose 2), Placebo	Lutris Pharma Ltd.	EGFRI Induced Acneiform Lesions	03/24	05/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Purim, Ofer
NCT04759664: LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC	Recruiting	2	117	US, RoW	LUT014 Gel (Dose 1), LUT014 Gel (Dose 2), Placebo	Lutris Pharma Ltd.	EGFRI Induced Acneiform Lesions	03/24	05/24
NCT06478862: Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy	Active, not recruiting	2	20	RoW	Promitil, Pegylated Liposomal Mitomycin-C Lipid-based Prodrug	Lipomedix Pharmaceuticals Inc.	Cancer of Ovary, Pancreatic Ductal Adenocarcinoma	06/26	01/27
Sapir, Eli
NANORAY-312, NCT04892173 / 2021-002163-22: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC	Recruiting	3	500	Europe, Japan, US, RoW	JNJ-90301900 (NBTXR3), Functionalized hafnium oxide nanoparticles, NBTXR3, Cetuximab, Erbitux, Radiation Therapy	Johnson & Johnson Enterprise Innovation Inc., Nanobiotix SA	Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged	06/26	06/27
Ryvo, Larisa
NCT04759664: LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC	Recruiting	2	117	US, RoW	LUT014 Gel (Dose 1), LUT014 Gel (Dose 2), Placebo	Lutris Pharma Ltd.	EGFRI Induced Acneiform Lesions	03/24	05/24